Truist maintains Eli Lilly stock Buy rating, $1038 target
Truist Securities reaffirmed its Buy rating and $1,038.00 price target for Eli Lilly and Company (NYSE:LLY) shares, with analyst targets ranging from $580 to $1,190. The company, which has ...
Ozempic-Type Drug Fails To Slow Parkinson’s, Study Finds
WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...
Daily13 小时
Use of Semaglutide and tirzepatide use linked to ophthalmic complications, finds study
Almost 2% of the U.S. population received prescriptions for the weight-loss and diabetes drugs semaglutide and tirzepatide in ...
Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today
Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...
Swissinfo15 小时
Swiss study sheds light on link between obesity and metabolic diseases
ETH Zurich researchers collected cells from overweight individuals to identify biological markers that raise the risk of metabolic diseases.
Ozempic-like drug fails to treat Parkinson's disease in new study; here's what the ...
A new study reveals disappointing results on the potential of GLP-1 drugs like Ozempic to treat Parkinson's disease. Despite ...
Prescriptions for weight loss drugs are skyrocketing, especially among young women. Experts ...
The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...
Ozempic-like jab 'fails' for millions with condition, study finds
A gold-standard University College of London study found a type of weight-loss jab had no benefit in alleviating a condition ...